DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breas
The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.